Short Interest in Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) Declines By 19.5%

Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) was the recipient of a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 9,900 shares, a decrease of 19.5% from the February 13th total of 12,300 shares. Based on an average trading volume of 5,900 shares, the short-interest ratio is presently 1.7 days.

Clinuvel Pharmaceuticals Price Performance

Shares of CLVLY opened at $7.72 on Thursday. The business’s 50 day moving average is $7.41 and its 200 day moving average is $8.41. Clinuvel Pharmaceuticals has a 12-month low of $6.80 and a 12-month high of $11.40.

Clinuvel Pharmaceuticals Company Profile

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).